Welchol is the first and only therapy approved as an adjunct to diet and exercise, to reduce both A1C and LDL-C for adult patients with type 2 diabetes and/or primary hyperlipidemia. Make Welchol your first-choice add-on therapy to help them achieve their goals.
The American Diabetes Association (ADA) and the American College of Cardiology (ACC) emphasize that it is critical to reduce both A1C and LDL-C in patients with type 2 diabetes.1-4
Nearly 40% of adults with T2DM also have elevated LDL-C5
Patients with T2DM have a CVD risk equivalent to that of a post-MI patient6
1. Bays HE, Goldberg RB, Truitt KE, Jones MR. Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects. Arch Intern Med. 2008;168(18):1975-1983.
3. Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care. 2008;31(4):811-822.
4. Buse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation. 2007;115:114-126. http://circ.ahajournals.org/cgi/content/full/115/1/114. Accessed April 26, 2010.
5. 2004 National Healthcare Quality Report (NHQR). US Dept. of Health and Human Services. March 2005. AHRQ Publication No. 05 0013.
6. US Department of Health and Human Services. National Institutes of Health. National Heart, Lung, and Blood Institute. Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Final Report. September, 2002. NIH Publication No. 02-5215. http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3full.pdf. Accessed April 26, 2010.
